

GWAS Meta-Analysis of Neuroticism (N=449,484) Identifies Novel Genetic Loci and Pathways

Mats Nagel^{1,2†}, Philip R Jansen^{1,3†}, Sven Stringer¹, Kyoko Watanabe¹, Christiaan A de Leeuw¹, Julien Bryois⁴, Jeanne E Savage¹, Anke R Hammerschlag¹, Nathan Skene⁵, Ana B Muñoz-Manchado⁵, the 23andMe Research Team⁶, Sten Linnarsson⁵, Jens Hjerling-Leffler⁵, Tonya JH White³, Henning Tiemeier^{3,7}, Tinca JC Polderman¹, Patrick F Sullivan^{4,8,9}, Sophie van der Sluis^{1,2§}, Danielle Posthuma^{1,2§*}

Affiliations:

- ¹ Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, The Netherlands
- ² Department of Clinical Genetics, Section Complex Trait Genetics, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands
- ³ Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, the Netherlands
- ⁴ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- ⁵ Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
- ⁶ 23andMe, Inc., Mountain View, CA, USA
- ⁷ Department of Psychiatry, Erasmus University Medical Center, Rotterdam, the Netherlands
- ⁸ Department of Genetics, University of North Carolina, Chapel Hill, USA
- ⁹ Department of Psychiatry, University of North Carolina, Chapel Hill, USA

† These authors contributed equally to this work

§ These authors jointly supervised this work

*Correspondence should be addressed to: Danielle Posthuma: Department of Complex Trait Genetics, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands. Phone: +31 20 598 2823, Fax: +31 20 5986926, d.posthuma@vu.nl

Word count: introductory paragraph: 150 main text: 1,498

Display items: 5 (Tables 1, Figures 4)

Includes **Online Methods, Supplementary Information** (Figures 14) and **Supplementary Tables** in excel 34.

Neuroticism is an important risk factor for psychiatric traits including depression¹, anxiety^{2,3}, and schizophrenia⁴⁻⁶. Previous genome-wide association studies⁷⁻¹² (GWAS) reported 16 genomic loci¹⁰⁻¹². Here we report the largest neuroticism GWAS meta-analysis to date (N=449,484), and identify 136 independent genome-wide significant loci (124 novel), implicating 599 genes. Extensive functional follow-up analyses show enrichment in several brain regions and involvement of specific cell-types, including dopaminergic neuroblasts ($P=3\times 10^{-8}$), medium spiny neurons ($P=4\times 10^{-8}$) and serotonergic neurons ($P=1\times 10^{-7}$). Gene-set analyses implicate three specific pathways: neurogenesis ($P=4.4\times 10^{-9}$), behavioural response to cocaine processes ($P=1.84\times 10^{-7}$), and axon part ($P=5.26\times 10^{-8}$). We show that neuroticism's genetic signal partly originates in two genetically distinguishable subclusters¹³ (*depressed affect* and *worry*, the former being genetically strongly related to depression, $r_g=0.84$), suggesting distinct causal mechanisms for subtypes of individuals. These results vastly enhance our neurobiological understanding of neuroticism, and provide specific leads for functional follow-up experiments.

The neuroticism meta-analysis comprised data from the UK Biobank Study (UKB, full release¹⁴; N=372,903; **Online Methods; Supplementary Fig. 1**), 23andMe, Inc.¹⁵ (N=59,206), and the Genetics of Personality Consortium (GPC⁹; N=17,375; **Online Methods**, N=449,484 in total). In all samples, neuroticism was measured through (digital) questionnaires (**Online Methods; Supplementary Information**). SNP associations were meta-analyzed using METAL¹⁶, weighted by sample size (**Online Methods**). The quantile-quantile (Q-Q) plot of the genome-wide meta-analysis on 449,484 subjects and 14,978,477 SNPs showed high inflation ($\lambda=1.65$) and mean χ^2 statistic (1.91) (**Fig. 1a; Supplementary Table 1**). The LD score regression (LDSC)^{17,18} intercept (1.02; SE=0.01) was consistent with

inflation due to true polygenicity and large sample size. The LDSC SNP-based heritability (h^2_{SNP}) of neuroticism was 0.100 (SE=0.003).

The GWAS meta-analysis identified 9,745 genome-wide significant (GWS) SNPs ($P < 5 \times 10^{-8}$), of which 157 and 2,414 were located in known associated inversions on chromosomes 8 and 17¹⁰⁻¹², respectively (**Supplementary Table 2; Fig. 1b; Supplementary Fig. 2**). FUMA¹⁹, a tool to functionally map and annotate GWAS results (**Online Methods**), extracted 170 independent lead SNPs (158 novel; see **Supplementary information** for definition of lead SNPs), which mapped to 136 independent genomic loci (124 novel; **Online Methods; Supplementary information; Supplementary Table 3-8**). Of all lead SNPs, 4 were in exonic, 88 in intronic, and 52 in intergenic regions. Of the 17,794 SNPs in high LD with one of the independent significant SNPs (see **Supplementary information** for definition of independent significant SNPs), most were intronic (9,147: 51,4%) or intergenic (5,460: 30,7%), and 3.8% was annotated as potentially having a functional impact, with 0.9% (155 SNPs) being exonic (**Fig. 1c, Supplementary Table 9**; see **Supplementary Tables 10-11** for an overview of chromatin state and regulatory functions of these SNPs). Of these, 37 were exonic non-synonymous (ExNS) (**Table 1, Supplementary Table 12**). The highest CADD score (34) of ExNS SNPs was for rs17651549, in exon 6 of *MAPT*, with a GWAS P -value of 1.11×10^{-28} , in high LD with the lead SNP in that region ($r^2=0.97$). rs17651549 is a missense mutation leading to an Arginine to Tryptophan change with allele frequencies matching the inversion in that region. The ancestral allele C is associated with a lower neuroticism score (see **Table 1** and **Supplementary Table 12** for a detailed overview of all functional variants in genomic risk loci).

Stratified LDSC²⁰ (**Online Methods**), showed significant enrichment for h^2 of SNPs located in conserved regions (enrichment=13.79, $P=5.14 \times 10^{-16}$), intronic regions (enrichment=1.27,

$P=1.27\times 10^{-6}$), and in H3K4me3 (enrichment=2.14, $P=1.02\times 10^{-5}$) and H3K9ac regions (enrichment=2.17, $P=3.06\times 10^{-4}$) (**Fig. 1d; Supplementary Table 13**).

Polygenic scores (PGS) calculated using PRSice²¹ (clumping followed by P -value thresholding) and LDpred²² in three randomly drawn hold-out samples (UKB only, N=3,000 each; **Online Methods**), explained up to 4.2% ($P=1.49\times 10^{-30}$) of the variance in neuroticism (**Supplementary Fig. 3; Supplementary Table 14**).

We used four strategies to link our SNP results to genes: positional, eQTL, and chromatin interaction mapping (**Online Methods**) and genome-wide gene-association analysis (GWGAS; MAGMA²³). GWGAS evaluates the joint association effect of all SNPs within a gene yielding a gene-based P -value. Based on our meta-analytic results, 283 genes were implicated through positional mapping, 369 through eQTL-mapping, and 119 through chromatin interaction-mapping (**Fig. 2a; Supplementary Table 15**). GWGAS identified 336 GWS genes ($P<2.75\times 10^{-6}$, **Figs. 2b-c; Supplementary Table 16, Supplementary information**), of which 203 overlapped with genes implicated by FUMA, resulting in 599 unique neuroticism-related genes. Of these, 50 were implicated by all four methods, of which 49 had chromatin interaction and eQTL associations in the same tissue/cell type (**Fig. 2a, Supplementary Table 15**).

19 of the 119 genes implicated through chromatin interaction mapping are especially interesting as they are implicated via interactions between two independent GWS genomic risk loci. There are several chromatin interactions in 7 tissue types (aorta, hippocampus, left ventricle, right ventricle, liver, spleen, pancreas) across two risk loci on chromosome 6 (**Fig. 3a**). Two genes are located in locus 45 and are mapped by chromatin interactions from risk locus 46 (*HFE* and *HIST1H4C*), and another 16 genes are coding histones in locus 46 and are mapped by interactions from locus 45 (**Supplementary Table 15**). *XKR6* is located on

chromosome 8 in risk locus 61, and is implicated by chromatin interactions in 5 tissue types (aorta, left ventricle, liver, pancreas and spleen) including cross locus interactions from locus 60 (**Fig. 3b; Supplementary Table 15**). This gene is also mapped by eQTLs in blood and transformed fibroblasts. Out of the 19 genes mapped by two loci, 4 are located outside of the risk loci (*HIST1H2AI*, *HIST1H3H*, *HIST1H2AK* and *HIST1H4L*), and 7 are also implicated by eQTLs in several tissue types (*HFE* in adipose subcutaneous, aorta, esophagus muscularis, lung, tibial nerve, sub-exposed skin and thyroid; *HIST1H4J* in blood and adrenal gland; and *HIST1H4K*, *HIST1H2AK*, *HIST1H2BO* and *XKR6* in blood).

Gene-based *P*-values were used for gene-set analysis in MAGMA^{23,26}, testing 7,246 pre-defined gene-sets derived from MsigDB²⁴, gene expression profiles in 53 tissue types obtained from the GTEx Project²⁵, and 24 cell-type specific expression profiles using RNAseq information²⁶ (**Online Methods**). Neuroticism was significantly associated with genes predominantly expressed in 11 brain tissue types (**Fig. 2d; Supplementary Table 17-18**) and with 7 gene ontology (GO) gene-sets, with the strongest association for neurogenesis ($P=0.0004$) and neuron differentiation ($P=0.002$) (**Supplementary Table 17**). Conditional gene-set analyses (**Online Methods**) suggested that 3 of the 7 gene-sets (neurogenesis, $P=4.4\times 10^{-9}$; behavioral response to cocaine, $P=1.84\times 10^{-7}$; axon part, $P=5.26\times 10^{-8}$) had largely independent associations, implying a role in neuroticism (**Supplementary Table 19**). Conditional analyses of the tissue-specific expression ascertained general involvement of (frontal) cortex expressed genes (**Supplementary Table 20; Supplementary Fig. 4**).

Cell type specific gene-set analysis showed significant association with genes expressed in multiple brain cell types (**Fig. 2e; Supplementary Table 21**), with dopaminergic neuroblasts ($P=3\times 10^{-8}$), medium spiny neurons ($P=4\times 10^{-8}$) and serotonergic neurons ($P=1\times 10^{-7}$) showing

the strongest associations, and conditional analysis indicated that these three cell types were also independently associated with neuroticism.

Aiming to further specify neuroticism's neurobiological interpretation, we compared the genetic signal of the full neuroticism trait to that of two genetically distinguishable neuroticism subclusters *depressed affect* and *worry*¹³ (**Online Methods**). As a validation of the *depressed affect* dimension, we also compare with GWAS results for depression. GWA analyses of the subclusters were conducted on the UKB-data only (dictated by item-level data availability; **Online Methods**; *depressed affect*, N=357,957; *worry*, N=348,219). For depression, our meta-analysis comprised data from the UKB¹⁴ (N=362,696; **Supplementary Fig. 5**), 23andMe¹⁵ (N=307,354), and the Psychiatric Genetics Consortium (PGC²⁷; N=18,759) (total N=688,809, not previously published; r_g between samples: 0.61-0.80; **Online Methods**; **Supplementary Table 22, Supplementary Information**). Genetic correlations of neuroticism with all three phenotypes were considerable (depression: $r_g=0.79$; *depressed affect*: $r_g=0.88$, *worry*: $r_g=0.87$; **Supplementary Table 23**).

The subclusters showed notable differences in genetic signal (e.g., exclusive GWS associations on chromosomes 2 and 19 for *depressed affect*, and chromosomes 3 and 22 for *worry*; **Supplementary Figs. 6-12; Supplementary Tables 24-26**). Of the 136 genetic loci associated with neuroticism, 32 were also GWS for *depressed affect* (7 shared with depression) but not for *worry*, and 26 were also GWS for *worry* (3 shared with depression) but not for *depressed affect* (**Supplementary Table 27; Supplementary Fig. 12**). These results were mirrored by gene-based analyses (**Supplementary information; Supplementary Tables 28-30; Supplementary Fig. 13**), suggesting that part of neuroticism's genetic signal originates specifically in one of the two subclusters, possibly implicating different causal genetic mechanisms .

To test specificity of the gene-sets implicated in neuroticism in the conditional analyses, we repeated the analyses, but now corrected for *depressed affect*, and *worry* scores, respectively (**Supplementary Table 31; Supplementary Fig. 14**). The association with ‘axon-part’ was markedly lower after correction for *worry* scores (uncorrected $P=5.26 \times 10^{-8}$; corrected for *depressed affect* $P=2.42 \times 10^{-6}$; corrected for *worry* $P=.0013$), suggesting that the involvement of ‘axon-part’ in neuroticism originates predominantly from the *worry*-component.

To examine the genetic correlational pattern of neuroticism, and to compare it to the patterns observed for depression, *depressed affect* and *worry*, we used LDSC to calculate genetic correlations with 35 traits for which large-scale GWAS summary statistics were available (**Supplementary Table 32; Online Methods**). We observed 11 Bonferroni-corrected significant genetic correlations for neuroticism ($\alpha=0.05/(4 \times 35)$; $P < 3.6 \times 10^{-4}$) (**Fig. 4; Supplementary Table 33**), covering previously reported psychiatric traits (r_g range: .20-.82) and subjective well-being ($r_g = -.68$). These correlations were supported by enrichment of neuroticism genes in sets of genes previously implicated in psychiatric traits (**Supplementary Table 34**). The r_g ’s of depression and *depressed affect* strongly mirrored each other (correlation between their r_g ’s is $r=.98$; **Supplementary information**), validating the *depressed affect* cluster. The correlational patterns for *depressed affect* and *worry* were markedly different and sometimes antipodal, with the genetic signal of the full neuroticism trait being a blend of both.

In conclusion, we identified 119 novel genetic loci for neuroticism. Extensive functional annotations highlighted several genes being implicated through multiple routes. We demonstrated the involvement of specific neuronal cell types and three independently associated genetic pathways, and established the genetic multidimensionality of the neuroticism phenotype, and its link with depression. The current study provides new leads, and

147 testable functional hypotheses for unraveling the neurobiology of neuroticism, its subtypes,
148 and genetically associated traits.
149

References and notes

1. Kendler, K. S. & Myers, J. The genetic and environmental relationship between major depression and the five-factor model of personality. *Psychol. Med.* **40**, 801–806 (2010).
2. Middeldorp, C. M. *et al.* The Association of Personality with Anxious and Depressive Psychopathology. *Biol. Personal. Individ. Differ.* 251–272 (2006).
3. Hettema, J. M., Neale, M. C., Myers, J. M., Prescott, C. A. & Kendler, K. S. A Population-Based Twin Study of the Relationship Between Neuroticism and Internalizing Disorders. *Am. J. Psychiatry* **163**, 857–864 (2006).
4. Hayes, J. F. *et al.* Association of Late Adolescent Personality With Risk for Subsequent Serious Mental Illness Among Men in a Swedish Nationwide Cohort Study. *JAMA Psychiatry* **54**, 948–963 (2017).
5. Smeland, O. B. *et al.* Identification of genetic loci shared between schizophrenia and the Big Five personality traits. *Sci. Rep.* **7**, 1–9 (2017).
6. Van Os, J. & Jones, P. B. Neuroticism as a risk factor for schizophrenia. *Psychol. Med.* **31**, 1129–1134 (2001).
7. Genetics of Personality Consortium. Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder. *JAMA Psychiatry* **72**, 642–650 (2015).
8. Terracciano, A. *et al.* Genome-wide association scan for five major dimensions of personality. *Mol. Psychiatry* **15**, 647–656 (2010).
9. Moor, M. H. M. De *et al.* Meta-analysis of genome-wide association studies for personality. *Mol. Psychiatry* **17**, 337–349 (2012).
10. Lo, M. *et al.* Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders. *Nat. Genet.* (2016). doi:10.1038/ng.3736
11. Smith, D. J. *et al.* Genome-wide analysis of over 106 000 individuals identifies 9

- neuroticism-associated loci. *Mol. Psychiatry* **21**, 1–9 (2016).
12. Okbay, A. *et al.* Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. *Nat. Genet.* **48**, 624–636 (2016).
13. Nagel, M., Watanabe, K., Stringer, S., Posthuma, D. & Van der Sluis, S. Item-level Analyses Reveal Genetic Heterogeneity in Neuroticism. Manuscript submitted for publication (2017).
14. Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv* (2017). at <<http://biorxiv.org/content/early/2017/07/20/166298.abstract>>
15. Eriksson, N. *et al.* Web-based, participant-driven studies yield novel genetic associations for common traits. *PLoS Genet.* **6**, 1–20 (2010).
16. Willer, C. J., Li, Y., Abecasis, G. R. & Overall, P. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
17. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
18. Bulik-Sullivan, B. K. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1–9 (2015).
19. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. FUMA: Functional mapping and annotation of genetic associations. *bioRxiv* (2017). at <<http://biorxiv.org/content/early/2017/02/20/110023.abstract>>
20. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
21. Euesden, J., Lewis, C. M. & O'Reilly, P. F. PRSice: Polygenic Risk Score software. *Bioinformatics* **31**, 1466–1468 (2015).
22. Vilhjálmsdóttir, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of

- 200 Polygenic Risk Scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).
- 201 23. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
202 Set Analysis of GWAS Data. *PLoS Comput. Biol.* **11**, 1–19 (2015).
- 203 24. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for
204 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci.* **102**, 15545–15550
205 (2005).
- 206 25. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue
207 gene regulation in humans. *Science (80-.)*. **348**, 648–660 (2015).
- 208 26. Skene, N. G. *et al.* Genetic Identification Of Brain Cell Types Underlying
209 Schizophrenia. *bioRxiv* (2017). at
210 <<http://biorxiv.org/content/early/2017/06/02/145466.abstract>>
- 211 27. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A
212 mega-analysis of genome-wide association studies for major depressive disorder. *Mol.*
213 *Psychiatry* **18**, 497–511 (2013).
- 214 28. Hyde, C. L. *et al.* Identification of 15 genetic loci associated with risk of major
215 depression in individuals of European descent. *Nat. Genet.* **48**, 1031–1036 (2016).
- 216 29. Eysenck, B. G., Eysenck, H. J. & Barrett, P. A Revised Version of the Psychoticism
217 Scale. *Pers. Individ. Dif.* **6**, 21–29 (1985).
- 218 30. John, O. P. & Srivastava, S. The Big Five trait taxonomy: History, measurement, and
219 theoretical perspectives. *Handb. Personal. Theory Res.* **2**, 102–138 (1999).
- 220 31. Soto, C. J. & John, O. P. Ten facet scales for the Big Five Inventory: Convergence with
221 NEO PI-R facets, self-peer agreement, and discriminant validity. *J. Res. Pers.* **43**, 84–
222 90 (2009).
- 223 32. Costa, P. & McCrae. *Professional Manual: Revised NEO Personality Inventory (NEO-*
224 *PI-R) and NEO Five-Factor-Inventory (NEO-FFI)*. (Psychological Assessment

Resources: Odessa, FL, 1992).

33. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).

34. Webb, B. T. *et al.* Molecular Genetic Influences on Normative and Problematic Alcohol Use in a Population-Based Sample of College Students. *Front. Genet.* **8**, 1–11 (2017).

35. Abraham, G. & Inouye, M. Fast Principal Component Analysis of Large-Scale Genome-Wide Data. *PLoS One* **9**, 1–5 (2014).

36. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

37. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 1 (2015).

38. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–315 (2014).

39. Schmitt, A. D. *et al.* A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. *Cell Rep.* **17**, 2042–2059 (2016).

40. Roadmap Epigenomics Consortium *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, (2015).

41. Croft, D. *et al.* The Reactome pathway knowledgebase. *Nucleic Acids Res.* **42**, D472–D477 (2014).

42. Coleman, J. *et al.* Functional consequences of genetic loci associated with intelligence in a meta-analysis of 87,740 individuals. *bioRxiv* (2017). at <http://biorxiv.org/content/early/2017/07/31/170712.abstract>

43. Gazal, S. *et al.* Linkage disequilibrium dependent architecture of human complex traits reveals action of negative selection. *bioRxiv* (2016). at <http://biorxiv.org/content/early/2016/10/19/082024.abstract>

250

251 **URLs:**

252 <http://ukbiobank.ac.uk>

253 <http://ctg.cncr.nl/software/magma>

254 <http://software.broadinstitute.org/gsea/msigdb/collections.jsp>

255 http://genome.sph.umich.edu/wiki/METAL_Program

256 <https://github.com/bulik/ldsc>

257 <http://fuma.ctglab.nl>

258

259 **Acknowledgements:** This work was funded by The Netherlands Organization for Scientific
 260 Research (NWO Brain & Cognition 433-09-228, NWO MagW VIDI 452-12-014, NWO VICI
 261 435-14-005 and 453-07-001, 645-000-003), Sophia Foundation for Scientific Research
 262 (SSWO, grant nr: S-1427). JB was funded by the Swiss National Science Foundation. Analyses
 263 were carried out on the Genetic Cluster Computer, which is financed by the Netherlands
 264 Scientific Organization (NWO: 480-05-003), by the VU University, Amsterdam, the
 265 Netherlands, and by the Dutch Brain Foundation, and is hosted by the Dutch National
 266 Computing and Networking Services SurfSARA. This research has been conducted using the
 267 UK Biobank Resource (application number 16406). We would like to thank the participants,
 268 including the 23andMe customers who consented to participate in research, and researchers
 269 who collected and contributed to the data.

270

271 **Author Contributions:** S.vd.S and D.P. conceived the study. M.N. and P.R.J. performed the
 272 analyses. S. St. performed the quality control on the UK Biobank data and wrote a pipeline to
 273 facilitate data processing. K.W. constructed the tool for biological annotation and ran the
 274 analyses. J.B. and P.F.S. performed the single-cell gene-expression analysis. M.N., P.R.J.,
 275 S.vd.S and D.P. wrote the paper. All authors discussed the results and commented on the paper.

276

277 **23andMe Research Team contributors:** Michelle Agee, Babak Alipanahi, Adam Auton,
 278 Robert K. Bell, Katarzyna Bryc, Sarah L. Elson, Pierre Fontanillas, Nicholas A. Furlotte, David
 279 A. Hinds, Bethann S. Hromatka, Karen E. Huber, Aaron Kleinman, Nadia K. Litterman,
 280 Matthew H. McIntyre, Joanna L. Mountain, Elizabeth S. Noblin, Carrie A.M. Northover,
 281 Steven J. Pitts, J. Fah Sathirapongsasuti, Olga V. Sazonova, Janie F. Shelton, Suyash
 282 Shringarpure, Chao Tian, Joyce Y. Tung, Vladimir Vacic, and Catherine H. Wilson.

283

284 **Author Information:** Reprints and permissions information is available at
 285 www.nature.com/reprints. The authors declare no competing financial interest.
 286 Correspondence and requests for materials should be addressed to d.posthuma@vu.nl.

287

288 **Table 1. Exonic non-synonymous (ExNS) variants in the genomic loci associated with neuroticism and in LD ($r^2>0.6$) with one of the**
289 **independent GWS SNPs.**


290 CADD: CADD score; rdb: regulome DB score; MAF: minor allele frequency; Z-score: z-score from the GWAS meta-analysis in METAL. Results
291 are reported on hg19 coordinates (NCBI b37). Genes containing multiple ExNS are annotated in red.
292

rsID	Exon	Gene	A1	MAF	gwas <i>P</i>	beta	r^2	Independent Sign. SNP	Locus	CADD	RDB	Min. Chromatin state
rs41266050	14	RABGAP1L	T	0.25	5.65E-06	-4.54	0.84	rs7536102	6	2.85	7	5
rs2073498	2	RASSF1	A	0.11	2.71E-08	5.56	0.98	rs6776145	25	19.43	7	3
rs111177	3	GNL3	A	0.38	2.49E-07	-5.16	0.75	rs2015971	26	22.90	NA	1
rs2289247	11	GNL3	A	0.41	2.28E-06	-4.73	0.65	rs2015971	26	12.82	NA	3
rs1029871	4	NEK4	C	0.38	2.29E-07	-5.17	0.75	rs2015971	26	24.10	1f	2
rs240780	39	ASCC3	C	0.43	3.01E-08	5.54	0.96	rs240769	49	19.95	7	4
rs11765552	11	LMTK2	A	0.46	7.68E-08	5.38	0.98	rs34320230	55	12.24	6	4
rs41274386	2	FAM120AOS	T	0.08	1.10E-07	5.31	0.66	rs78046549	71	2.36	4	1
rs1055710	1	FAM120AOS	A	0.33	1.11E-09	-6.09	0.99	rs10821129	71	0.05	NA	1
rs3816614	33	LRP4	T	0.23	5.69E-07	5.00	0.90	rs7940441	84	22.70	NA	4
rs2030166	5	NDUFS3	T	0.35	2.02E-10	-6.36	0.93	rs11039389	84	3.13	6	4
rs1064608	13	MTCH2	C	0.35	1.15E-10	-6.45	0.93	rs11039389	84	25.40	6	4
rs12286721	13	AGBL2	A	0.45	7.81E-08	-5.37	0.78	rs7107356	84	14.22	1f	5
rs4926	8	SERPING1	A	0.27	6.12E-07	4.99	0.86	rs73480560	85	23.50	5	4
rs11604671	6	ANKK1	A	0.49	2.57E-10	-6.32	0.64	rs2186800	88	1.39	5	4
rs1800497	8	ANKK1	A	0.20	8.45E-06	4.45	0.69	rs11214607	88	0.81	NA	4
rs7298565	12	UBE3B	A	0.48	2.24E-10	6.34	0.76	rs2111216	94	22.70	6	4
rs8007859	10	EXD2	T	0.39	2.28E-08	5.59	0.80	rs1275411	108	3.95	5	4
rs2286913	4	RPS6KL1	A	0.37	1.46E-07	5.26	0.89	rs3213716	110	12.96	5	2
rs7156590	3	RPS6KL1	T	0.37	2.79E-07	5.14	0.86	rs3213716	110	19.46	5	4
rs12443627	1	ENSG00000268863	C	0.37	1.28E-10	6.43	0.77	rs3751855	119	3.58	2b	1
rs35713203	2	ZNF646	C	0.38	3.67E-11	-6.62	0.98	rs3751855	119	0.05	2b	3
rs7196726	2	ZNF646	A	0.38	1.29E-11	-6.77	1.00	rs3751855	119	0.00	2b	3
rs7199949	8	PRSS53	C	0.38	1.32E-11	-6.77	1.00	rs3751855	119	0.00	2b	2
rs3748400	12	ZCCHC14	T	0.23	8.83E-09	-5.75	0.98	rs2042395	122	24.00	5	4
rs12949256	1	ARHGAP27	T	0.19	1.47E-23	10.00	0.73	rs77804065	126	11.97	4	1
rs16940674	6	CRHR1	T	0.23	5.24E-29	11.18	0.97	rs77804065	126	12.86	1f	5
rs16940681	13	CRHR1	C	0.23	2.18E-30	11.46	0.97	rs77804065	126	1.76	4	5
rs242944	1	SPPL2C	A	0.44	2.88E-12	-6.98	1.00	rs242947	126	0.00	NA	5
rs62054815	1	SPPL2C	A	0.23	1.74E-30	11.48	0.97	rs77804065	126	0.00	5	5
rs12185233	1	SPPL2C	C	0.23	6.76E-29	11.16	0.96	rs77804065	126	25.60	1f	5
rs12373139	1	SPPL2C	A	0.23	2.19E-30	11.46	0.97	rs77804065	126	0.53	1f	5
rs63750417	6	MAPT	T	0.23	4.89E-30	11.39	0.97	rs77804065	126	8.68	5	4

293

rsID	Exon	Gene	A1	MAF	gwas <i>P</i>	beta	<i>r</i> ²	Independent Sign. SNP	Locus	CADD	RDB	Min. Chromatin state
rs62063786	6	MAPT	A	0.23	1.05E-29	11.32	0.97	rs77804065	126	7.65	5	4
rs17651549	6	MAPT	T	0.23	1.11E-28	11.11	0.97	rs77804065	126	34.00	1f	4
rs17522826	1	TCF4	A	0.18	2.17E-10	6.35	0.60	rs10503002	133	14.22	NA	1
rs139431	2	L3MBTL2	T	0.37	9.45E-07	-4.90	0.63	rs7289932	138	10.26	7	4

294



295

Fig. 1. SNP-based associations with neuroticism in the GWAS meta-analysis.

(a) Quantile-quantile plot of the SNP-based associations with neuroticism. **(b)** Manhattan plot showing the $-\log_{10}$ transformed P -value of each SNP on the y-axis and base pair positions along the chromosomes on the x-axis. The dashed line indicates genome-wide significance ($P < 5 \times 10^{-8}$), the dotted line the threshold for suggestive associations ($P < 1 \times 10^{-5}$). **(c)** Pie charts showing the distribution of functional consequences of SNPs in linkage disequilibrium (LD) with genome-wide significant lead SNPs in the meta-analysis, the minimum chromatin state across 127 tissue and cell types and the distribution of regulome DB score, a categorical score between 1a and 7, indicating biological evidence of a SNP being a regulatory element, with a low score denoting a higher likelihood of being regulatory. **(d)** Heritability enrichment of 22 functional SNP annotations calculated with stratified LD score regression.




Fig. 2. Mapping of genes and tissue- and cell expression profiles.

(a) Venn diagram showing overlap of genes implicated by positional mapping, eQTL mapping, chromatin interaction mapping, and gene-based genome-wide association (GWGAS). (b) Quantile-quantile plot of the GWGAS. (c) Manhattan plot of the genome-wide gene-based association analysis (GWGAS) on neuroticism. The y-axis shows the $-\log_{10}$ transformed P -value of each gene, and the chromosomal position (start position) on the x-axis. The dashed line indicates the threshold for genome-wide significance of the gene-based test ($P < 2.76 \times 10^{-6}$; 0.05/18,128), and the dotted line indicates the suggestive threshold ($P < 2.76 \times 10^{-5}$; 0.5/18,128). (d) Gene expression profiles of identified genes for 53 tissue types. Expression data were extracted from the Genotype-Tissue Expression (GTEx) database. Expression values (RPKM) were $\log_2$ transformed with pseudocount 1 after winsorization at 50 and averaged per tissue. Gene-set tests for tissue expressions were calculated using MAGMA (Online Methods). (e) Enrichment of genetic signal for neuroticism in 24 brain cell types. The dashed line indicates the Bonferroni-corrected significance threshold ($P = 0.05/7,323 = 6.83 \times 10^{-6}$).




Fig 3. Genomic risk loci, eQTL associations and chromatin interaction for chromosome 6 and 8, containing cross-locus interactions.

Circos plot showing genes on (a) chromosome 6 and (b) chromosome 8 that were implicated by the genomic risk (blue areas) loci by chromatin interaction (CTI; orange), eQTL (green) or implicated by both eQTL and CTI mapping (red). The outer layer shows a Manhattan plot containing the $-\log_{10}$ transformed P -value of each SNP in the GWAS meta-analysis. Empty regions in the Manhattan plot layer indicate regions where no SNPs with $P < 0.05$ are situated.




Fig. 4. Genetic correlations between neuroticism and other traits.

Genetic correlations of neuroticism, depression, *depressed* affect and worry with various traits and diseases. LD score regression (**Online Methods**) tested genome-wide SNP associations for the neuroticism score against previously published results for 35 neuropsychiatric outcomes, antropometric and health-related traits, and brain morphology (**Supplementary Table 32-33**).

Online methods

Samples

UK Biobank: The UK Biobank (UKB) Study is a major data resource, containing genetic and a wide range of phenotypic data of ~500,000 participants aged 40-69 at recruitment¹⁴. We used data released in July 2017, and selection (discussed below) resulted in final sample sizes of N=372,903 and N=362,696 individuals for neuroticism and depression, respectively (**Supplementary information**). The UKB received ethical approval from the National Research Ethics Service Committee North West–Haydock (reference 11/NW/0382), and all study procedures were performed in accordance with the World Medical Association for medical research. The current study was conducted under UKB application number 16406.

23andMe: 23andMe, Inc. is a large personal genomics company that provides genotype and health-related information to customers. For the neuroticism meta-analysis, we used neuroticism GWAS summary statistics from a subset of 23andMe research participants (N=59,206), described in more detail elsewhere¹⁰. For our depression meta-analysis, we used depression GWAS summary statistics from a subset of 23andMe research participants (N=307,354), described in detail elsewhere²⁸. All included participants provided informed consent and were of European ancestry, and related individuals were excluded. Online data collection procedures were approved by the Ethical & Independent Review Services (E&I Review), an AAHRPP-accredited private institutional review board (<http://www.eandireview.com>).

Genetics of Personality Consortium: The Genetics of Personality Consortium (GCP) is a large body of cooperation concerning GWAS on personality. We used summary statistics of neuroticism from the first GCP personality meta-analysis (GPC1, <http://www.tweelingenregister.org/GPC/>)⁹, on 10 discovery cohorts (SardiNIA, NTR/NESDA,

ERF, SAGE, HBCS, NAG, IRPG, QIMR, LBC1936, BLSA, EGPOT), including in total N=17,375 participants of European descent. All included studies were approved by local ethic committees, and informed consent was obtained from all participants.

Psychiatric Genetics Consortium: The Psychiatric Genetics Consortium (PGC) unites investigators worldwide to conduct genetic meta- and mega-analyses for psychiatric disorders. We used summary statistics from the latest published PGC meta-analysis on depression (<http://www.med.unc.edu/pgc/results-and-downloads>)²⁷, which included data from 8 cohorts (Bonn/Mannheim, GAIN, GenRED, GSK, MDD2000, MPIP, RADIANT, STAR*D), covering N=18,759 participants of European descent. All included studies were approved by local ethic committees, and informed consent was obtained from all participants.

Phenotype assessment – Neuroticism

UK Biobank: Neuroticism was measured with 12 dichotomous (yes/no) items of the Eysenck Personality Questionnaire Revised Short Form (EPQ-RS)²⁹, using a touchscreen-questionnaire at the UKB assessment centers (**Supplementary Information 1.1**). Participants with valid responses to <10 items were excluded from analyses. A weighted neuroticism sum score was calculated by adding up individual valid item responses, and dividing that sum by the total number of valid responses. Scores on 4 EPQ-RS items (i.e., “Do you often feel lonely?”, “Do you ever feel ‘just miserable’ for no reason?”, “Does your mood often go up and down?”, and “Do you often feel ‘fed-up’?”) were summed to obtain scores for the cluster *depressed affect*. Similarly, scores on 4 other EPQ-RS items (i.e., “Are you a worried?”, “Do you suffer from nerves?”, “Would you call yourself a nervous person?”, and “Would you call yourself tense or highly strung”) were summed to obtain scores for the cluster *worry*. In the item-cluster analyses, only participants with complete scores on all 4 items were included, resulting in N=357,957 and N=348,219 for *depressed affect* and *worry*, respectively.

23andMe: Neuroticism was operationalized as of the sum of 8 neuroticism items (5-point Likert scale; ‘Disagree strongly’ to ‘Agree strongly’) from the Big Five Inventory (BFI^{30,31}), as obtained in an online survey. Only participants with valid responses to all items were included in the analyses (**Supplementary Information 1.2**).

Genetic Personality Consortium: All 10 cohorts included in the first meta-analysis of the GPC used sums of the scores on 12 items (5-point Likert scale; ‘Strongly disagree’ to ‘Strongly agree’) of the NEO-FFI³² to measure neuroticism. If <4 item scores were missing, data on invalid items were imputed by taking an individual’s average score on valid items. Participants were excluded from analyses if they had invalid scores on >3 items⁹ (**Supplementary Information 1.3**).

Phenotype assessment - Depression

UK Biobank: Depression was operationalized by adding up the scores on two continuous items (“Over the past two weeks, how often have you felt down, depressed or hopeless?”, “Over the past two weeks, how often have you had little interest or pleasure in doing things?”; both evaluated on a 4-point Likert scale; ‘Not at all’ to ‘Nearly every day’), resulting in a continuous depression score (as used previously¹²). Only participants with scores on both items were included in the analyses, resulting in N=362,696 (**Supplementary Information 1.4**).

23andMe: This concerns a case-control sample. Four self-report survey items were used to determine case-control status. Cases were defined as replying affirmatively to at least one of these questions, and not replying negatively to previous ones. Controls replied negatively to at least one of the questions, and did not report being diagnosed with depression on previous ones (**Supplementary Information 1.5**).

Psychiatric Genetics Consortium: This concerns a case-control sample. Cases had a DSM-IV lifetime (sometimes (early onset) recurrent) major depressive disorder (MDD) diagnosis, either established through structured diagnostic interviews or clinician-administered DSM-IV checklists. Most cases were ascertained from clinical sources, while controls were randomly selected from population resources and screened for lifetime history of MDD²⁷ (Supplementary Information 1.6).

Genotyping and imputation

UK Biobank - Neuroticism: We used genotype data released by the UKB in July 2017. The genotype data collection and processing are described in detail by the responsible UKB group¹⁴. In short, 489,212 individuals were genotyped on two customized SNP arrays (the UK BiLEVE Axiom array (n=50,520) and UK Biobank Axiom array (n=438,692)), covering 812,428 unique genetic markers (95% overlap in SNP content). After quality control procedures¹⁴, 488,377 individuals and 805,426 genotypes remained. Genotypes were phased and imputed by the coordinating team to approximately 96 million genotypes using a combined reference panel including the Haplotype Reference Consortium and the UK10K haplotype panel. Imputed and quality controlled genotype data was available for 487,422 individuals and 92,693,895 genetic variants. As recommended by the UKB team, variants imputed from the UK10K reference panel were removed from the analyses due to technical errors in the imputation process.

In our analyses, only individuals from European descent (based on genetic principal components) were included. Therefore principal components from the 1000 Genomes reference populations³³ were projected onto the called genotypes available in UK Biobank. Subjects were identified as European if their projected principal component score was closest (based on the Mahalanobis distance) to the average score of the European 1000 Genomes

sample³⁴. European subjects with a Mahalanobis distance > 6 S.D. were excluded. In addition, participants were excluded based on withdrawn consent, UKB provided relatedness (subjects with most inferred relatives, 3rd degree or closer, were removed until no related subjects were present), discordant sex, sex aneuploidy. After selecting individuals based on available neuroticism sum-score and active consent for participation, 372,903 individuals remained for the analyses.

To correct for population-stratification, 30 principal components were calculated on the subset of QC-ed unrelated European subjects based on 145,432 independent ($r^2 < 0.1$) SNPs with MAF > 0.01 and INFO = 1 using FlashPC³⁵. Subsequently, imputed variants were converted to hard call using a certainty threshold of 0.9. Multi-allelic SNPs, indels, and SNPs without unique rs id were excluded, as well as SNPs with a low imputation score (INFO score < 0.9), low minor allele frequency (MAF < 0.0001) and high missingness (> 0.05). This resulted in a total of 10,847,151 SNPs used for downstream analysis.

UK Biobank – Depression: Similar genotyping/imputation/filtering procedures as described above for the UKB neuroticism GWAS were followed for the UKB depression GWAS, resulting in N = 362,696.

Other samples: Summary statistics were used for 23andMe and PGC. Genotyping and imputation of these samples are described in detail elsewhere (23andMe depression²⁸; PGC depression²⁷).

Genome-wide association analyses

UK Biobank - Neuroticism: Genome-wide association analyses were performed in PLINK^{36,37}, using a linear regression model of additive allelic effects with age, sex, townsend deprivation index, genotype array, and 10 genetic European-based principal components as covariates.

UK Biobank – Depression, depressed affect, worry: The settings, covariates, and exclusion criteria for the UKB depression, UKB *depressed affect*, and UKB *worry* GWAS were the same as described above for UKB neuroticism GWAS, with 10,847,151 SNPs remaining after all exclusion steps.

Other samples: Summary statistics were used for 23andMe, GPC and PGC. Details on the genome-wide association analyses of these samples can be found elsewhere (23andMe neuroticism¹⁰; 23andMe depression²⁸; GPC neuroticism⁹; PGC depression²⁷).

Meta-analysis

Neuroticism: Meta-analysis of the neuroticism GWAS in UKB, 23andMe, and GPC was carried out in METAL¹⁶. The meta-analysis was performed on the *P*-value of each SNP using a sample size-weighted fixed-effects analysis. Bonferroni correction was applied to correct for multiple testing. The genetic signal correlated strongly between the three samples (r_g range: 0.83 – 1.07; **Supplementary Table 1**), supporting the decision to meta-analyze.

Depression: Meta-analysis of the depression GWAS in UKB, 23andMe and PGC was carried out in METAL¹⁶. As the UKB GWAS concerned a continuous operationalization of the depression phenotype, while 23andMe and PGC used case-control phenotypes, the odds ratio from the 23andMe and PGC summary statistics were converted to log odds, reflecting the direction of the effect. The meta-analysis was then performed on the *P*-value of each SNP using a sample size-weighted fixed-effects analysis. Bonferroni correction was applied to correct for multiple testing. Genetic correlations between the three samples were moderate to strong (r_g range: 0.61 – 0.80; **Supplementary Table 22**).

Functional Annotation

Functional annotation was performed using FUMA¹⁷ (<http://fuma.ctglab.nl/>), an online platform for functional mapping of genetic variants. We first defined independent significant SNPs which have a genome-wide significant P -value (5×10^{-8}) and are independent at $r^2 < 0.6$. Lead SNPs were defined by retaining those independent significant SNPs that were independent from each other at $r^2 < 0.1$ (based on LD information from UK Biobank genotypes; see **Supplementary Information** for a more detailed explanation). Subsequently, risk loci were defined by merging lead SNPs that physically overlapped or whose LD blocks were closer than 250kb apart. As a result, when analyzing multiple phenotypes, as in the current study, the same locus may be discovered for different phenotypes, whilst different lead SNPs are identified.

We selected all SNPs with $r^2 > 0.6$ with one of the independent significant SNPs, a P -value lower than 0.05 and minor allele frequency (MAF) higher than 0.0001 for annotations. Functional consequences for all independent significant SNPs and SNPs in LD with them were obtained by performing ANNOVAR gene-based annotation using Ensembl genes. In addition, CADD scores (indicating the deleteriousness of SNP, with scores > 12.37 seen as likely deleterious)³⁸ and RegulomeDB scores (with lower scores indicating a higher probability of having a regulatory function) were annotated to SNPs by matching chromosome, position, reference and alternative alleles.

Gene-mapping

SNPs in genomic risk loci that were GWS or were in LD (> 0.6) with one of the independent GWS SNPs were mapped to genes in FUMA¹⁹ using three strategies:

1. Positional mapping maps SNPs to genes based on the physical distances (i.e., within 10kb window) from known protein coding genes in the human reference assembly (GRCh37/hg19).
2. eQTL mapping maps SNPs to genes with which they show a significant eQTL association (i.e. the expression of that gene is associated with allelic variation at the SNP). eQTL mapping uses information from 3 data repositories (GTEx, Blood eQTL browser BIOS QTL browser, and is based on cis-eQTLs which can map SNPs to genes up to 1Mb apart. A false discovery rate (FDR) of 0.05 was applied to define significant eQTL associations.
3. Chromatin interaction mapping was performed to map SNPs to genes based on a significant chromatin interaction between a genomic region in a risk locus and promoter regions of genes (250bp up and 500bp downstream of transcription start site (TSS)). Chromatin interaction mapping can involve long-range interactions as it does not have a distance boundary as in eQTL mapping. FUMA currently contains Hi-C data of 14 tissue types from the study of³⁹. Since chromatin interactions are often defined in a certain resolution, such as 40kb, an interacting region may span multiple genes. All SNPs within these regions would be mapped by this method to genes in the corresponding interaction region. To further prioritize candidate genes from chromatin interaction mapping, we integrated predicted enhancers and promoters in 111 tissue/cell types from the Roadmap Epigenomics Project⁴⁰; chromatin interactions are selected in which one region involved in the interaction overlaps with predicted enhancers and the other region overlaps with predicted promoters in 250bp up- and 500bp downstream of TSS site of a gene. We used a FDR of 1×10^{-5} to define significant interactions.

Gene-based analysis

A genome-wide gene association analysis (GWGAS) can identify genes in which multiple SNPs show moderate association to the phenotype of interest without reaching the stringent genome-wide significance level. At the same time, as a GWGAS takes all SNPs within a gene into account, a gene harbouring a genome-wide significant SNP may not be implicated by a GWGAS analyses when multiple other SNPs within that gene show only very weak association signal. The *P*-values from the SNP-based GWAS meta-analyses for neuroticism and depression, and the GWAS for *depressed affect* and *worry*, were used as input for the genome-wide gene association analysis (GWGAS) in MAGMA (<http://ctg.cncr.nl/software/magma>)²³, and all 19,427 protein-coding genes from the NCBI 37.3 gene definitions were used. We annotated all SNPs in our GWA (meta-) analyses to these genes, resulting in 18,187, 18,187, 18,182, and 18,182 genes that were represented by at least one SNP in the neuroticism meta-analysis, the depression meta-analysis, the *depressed affect* GWAS, and the *worry* GWAS, respectively. We included a window around each gene of 2 kb before the transcription start site and 1 kb after the transcription stop site. Gene association tests were performed taking into account the LD between SNPs, and a stringent Bonferroni correction was applied to correct for multiple testing (0.05/number of genes tested: $P < 2.75 \times 10^{-6}$).

Gene-set analysis

We used MAGMA²³ to test for association of predefined gene-sets with neuroticism, depression, *depressed affect*, and *worry*. A total of 7,246 gene-sets were derived from several resources, including BioCarta, KEGG, Reactome⁴¹ and GO. All gene-sets were obtained from the MsigDB version 5.2 (<http://software.broadinstitute.org/gsea/msigdb/collections.jsp>). In addition, we performed gene-set analysis on 53 tissue expression profiles obtained from the GTEx portal (<https://www.gtexportal.org/home/>), and 24 cell-type specific expression profiles.

Definition and calculation of gene-sets for cell-type specific expression is described in detail elsewhere^{26,42}. Briefly, brain cell-type expression data was drawn from scRNAseq data from mouse brain²⁶. For each gene, the value for each cell-type was calculated by dividing the mean Unique Molecular Identifier (UMI) counts for the given cell type by the summed mean UMI counts across all cell types²⁶. Associations between gene-wise *P*-values from the meta-analysis and cell-type specific gene expression were calculated using MAGMA²³, by grouping genes into 40 equal bins by specificity of expression, and regressing bin-membership on gene-wise association with neuroticism in the meta-analysis. Results were considered significant if the association *P*-values were smaller than the relevant Bonferroni threshold.

For all gene-sets we computed competitive *P*-values, which result from the test whether the combined effect of genes in a gene-set is significantly larger than the combined effect of a same number of randomly selected genes (in contrast, self-contained *P*-values result from testing against the null hypothesis of no effect). We only report competitive *P*-values, which are more conservative compared to self-contained *P*-values. Competitive *P*-values were Bonferroni corrected ($\alpha=0.05/7,323=6.83\times 10^{-6}$).

Conditional gene-set analyses were performed with MAGMA as a secondary analysis to test whether each observed enriched cell-type was independent of all others. Full details of the method implemented are provided in ²⁶.

Genetic correlations

Genetic correlations (r_g) were computed using LDscore regression^{17,18} (<https://github.com/bulik/ldsc>). The significance of the genetic correlations of neuroticism, depression, *depressed affect* and *worry* with 35 behavioral, social and (mental) health phenotypes for which summary statistics were available was determined while correcting for

multiple testing through a stringent Bonferroni corrected threshold of $P < 0.05 / (4 \times 35)$ (3.6×10^{-4}).

Partitioned heritability

To investigate the relative contribution to the overall heritability of SNPs annotated to 22 specific genomic categories, we partitioned SNP heritability by binary annotations using stratified LD score regression^{20,43}. Information about binary SNP annotations were obtained from the LD score website (<https://github.com/bulik/ldsc>). Enrichment results reflect the X-fold increase in h^2 proportional to the number of SNPs (e.g., enrichment=13.79 for SNPs in conserved regions implies that a 13,79-fold increase in h^2 is carried by SNPs in these region, corrected for the proportion of SNPs in these regions compared to all tested SNPs).

Polygenic risk scoring

To test the predictive accuracy (ΔR^2) of the our meta-analytic results, we calculated a polygenic risk score (PGS) based on the SNP effect sizes of the current analysis. As independent samples we used holdout samples; we removed 3,000 individuals from the discovery sample (UKB only, as we only had access to raw data from this sample) and reran the genome-wide analyses. We repeated this three times, to create 3 randomly drawn, independent hold-out samples. Next, we calculated a PGS on the individuals in each of the 3 holdout samples. PGS were calculated using LDpred²² and PRSice²¹ (clumping followed by P -value thresholding).

For LDpred, PGS were calculated based on different LDpred priors ($P_{LDpred} = 0.01, 0.05, 0.1, 0.5, 1$ and infinitesimal). The explained variance (R^2) was derived from the linear model, using the neuroticism summary score as the outcome, while correcting for age, gender, array, batch and genetic principal components.

Data availability

Our policy is to make genome-wide summary statistics (sumstats) publically available. Sumstats from our neuroticism meta-analysis, our depression meta-analysis, and the GWA analyses for *depressed affect* and *worry* are available for download at <https://ctg.cncr.nl/>. Note that our freely available meta-analytic sumstats concern results excluding the 23andMe sample. This is a non-negotiable clause in the 23andMe data transfer agreement, intended to protect the privacy of the 23andMe research participants. To fully recreate our meta-analytic results for neuroticism: (a) obtain Lo et al. (2016) sumstats from 23andMe (see below); (b) conduct a meta-analysis of our sumstats with the Lo et al. sumstats. To fully recreate our meta-analytic results for depression: (a) obtain Hyde et al. (2016) sumstats from 23andMe (see below); (b) conduct a meta-analysis of our sumstats with the Hyde et al. sumstats. 23andMe participant data are shared according to community standards that have been developed to protect against breaches of privacy. Currently, these standards allow for the sharing of summary statistics for at most 10,000 SNPs. The full set of summary statistics can be made available to qualified investigators who enter into an agreement with 23andMe that protects participant confidentiality. Interested investigators should contact David Hinds (dhinds@23andme.com) for more information.

References

1. Kendler, K. S. & Myers, J. The genetic and environmental relationship between major depression and the five-factor model of personality. *Psychol. Med.* **40**, 801–806 (2010).
2. Middeldorp, C. M. *et al.* The Association of Personality with Anxious and Depressive Psychopathology. *Biol. Personal. Individ. Differ.* 251–272 (2006).
3. Hettema, J. M., Neale, M. C., Myers, J. M., Prescott, C. A. & Kendler, K. S. A Population-Based Twin Study of the Relationship Between Neuroticism and Internalizing Disorders. *Am. J. Psychiatry* **163**, 857–864 (2006).
4. Hayes, J. F. *et al.* Association of Late Adolescent Personality With Risk for Subsequent Serious Mental Illness Among Men in a Swedish Nationwide Cohort Study. *JAMA Psychiatry* **54**, 948–963 (2017).
5. Smeland, O. B. *et al.* Identification of genetic loci shared between schizophrenia and the Big Five personality traits. *Sci. Rep.* **7**, 1–9 (2017).
6. Van Os, J. & Jones, P. B. Neuroticism as a risk factor for schizophrenia. *Psychol. Med.* **31**, 1129–1134 (2001).
7. Genetics of Personality Consortium. Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder. *JAMA Psychiatry* **72**, 642–650 (2015).
8. Terracciano, A. *et al.* Genome-wide association scan for five major dimensions of personality. *Mol. Psychiatry* **15**, 647–656 (2010).
9. Moor, M. H. M. De *et al.* Meta-analysis of genome-wide association studies for personality. *Mol. Psychiatry* **17**, 337–349 (2012).
10. Lo, M. *et al.* Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders. *Nat. Genet.* (2016). doi:10.1038/ng.3736
11. Smith, D. J. *et al.* Genome-wide analysis of over 106 000 individuals identifies 9

- 655 neuroticism-associated loci. *Mol. Psychiatry* **21**, 1–9 (2016).
- 656 12. Okbay, A. *et al.* Genetic variants associated with subjective well-being, depressive
657 symptoms, and neuroticism identified through genome-wide analyses. *Nat. Genet.* **48**,
658 624–636 (2016).
- 659 13. Nagel, M., Watanabe, K., Stringer, S., Posthuma, D. & Van der Sluis, S. Item-level
660 Analyses Reveal Genetic Heterogeneity in Neuroticism. Manuscript submitted for
661 publication (2017).
- 662 14. Bycroft, C. *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants.
663 *bioRxiv* (2017). at <<http://biorxiv.org/content/early/2017/07/20/166298.abstract>>
- 664 15. Eriksson, N. *et al.* Web-based, participant-driven studies yield novel genetic
665 associations for common traits. *PLoS Genet.* **6**, 1–20 (2010).
- 666 16. Willer, C. J., Li, Y., Abecasis, G. R. & Overall, P. METAL: fast and efficient meta-
667 analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 668 17. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
669 polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 670 18. Bulik-Sullivan, B. K. *et al.* An atlas of genetic correlations across human diseases and
671 traits. *Nat. Genet.* **47**, 1–9 (2015).
- 672 19. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. FUMA: Functional
673 mapping and annotation of genetic associations. *bioRxiv* (2017). at
674 <<http://biorxiv.org/content/early/2017/02/20/110023.abstract>>
- 675 20. Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-
676 wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
- 677 21. Euesden, J., Lewis, C. M. & O'Reilly, P. F. PRSice: Polygenic Risk Score software.
678 *Bioinformatics* **31**, 1466–1468 (2015).
- 679 22. Vilhjálmsdóttir, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of

- 680 Polygenic Risk Scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).
- 681 23. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-
682 Set Analysis of GWAS Data. *PLoS Comput. Biol.* **11**, 1–19 (2015).
- 683 24. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for
684 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci.* **102**, 15545–15550
685 (2005).
- 686 25. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue
687 gene regulation in humans. *Science (80-.)*. **348**, 648–660 (2015).
- 688 26. Skene, N. G. *et al.* Genetic Identification Of Brain Cell Types Underlying
689 Schizophrenia. *bioRxiv* (2017). at
690 <<http://biorxiv.org/content/early/2017/06/02/145466.abstract>>
- 691 27. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A
692 mega-analysis of genome-wide association studies for major depressive disorder. *Mol.*
693 *Psychiatry* **18**, 497–511 (2013).
- 694 28. Hyde, C. L. *et al.* Identification of 15 genetic loci associated with risk of major
695 depression in individuals of European descent. *Nat. Genet.* **48**, 1031–1036 (2016).
- 696 29. Eysenck, B. G., Eysenck, H. J. & Barrett, P. A Revised Version of the Psychoticism
697 Scale. *Pers. Individ. Dif.* **6**, 21–29 (1985).
- 698 30. John, O. P. & Srivastava, S. The Big Five trait taxonomy: History, measurement, and
699 theoretical perspectives. *Handb. Personal. Theory Res.* **2**, 102–138 (1999).
- 700 31. Soto, C. J. & John, O. P. Ten facet scales for the Big Five Inventory: Convergence with
701 NEO PI-R facets, self-peer agreement, and discriminant validity. *J. Res. Pers.* **43**, 84–
702 90 (2009).
- 703 32. Costa, P. & McCrae. *Professional Manual: Revised NEO Personality Inventory (NEO-*
704 *PI-R) and NEO Five-Factor-Inventory (NEO-FFI)*. (Psychological Assessment

Resources: Odessa, FL, 1992).

33. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
34. Webb, B. T. *et al.* Molecular Genetic Influences on Normative and Problematic Alcohol Use in a Population-Based Sample of College Students. *Front. Genet.* **8**, 1–11 (2017).
35. Abraham, G. & Inouye, M. Fast Principal Component Analysis of Large-Scale Genome-Wide Data. *PLoS One* **9**, 1–5 (2014).
36. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
37. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 1 (2015).
38. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–315 (2014).
39. Schmitt, A. D. *et al.* A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. *Cell Rep.* **17**, 2042–2059 (2016).
40. Roadmap Epigenomics Consortium *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, (2015).
41. Croft, D. *et al.* The Reactome pathway knowledgebase. *Nucleic Acids Res.* **42**, D472–D477 (2014).
42. Coleman, J. *et al.* Functional consequences of genetic loci associated with intelligence in a meta-analysis of 87,740 individuals. *bioRxiv* (2017). at <http://biorxiv.org/content/early/2017/07/31/170712.abstract>
43. Gazal, S. *et al.* Linkage disequilibrium dependent architecture of human complex traits reveals action of negative selection. *bioRxiv* (2016). at <http://biorxiv.org/content/early/2016/10/19/082024.abstract>

730